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To investigate themechanisms of enhanced airway deposition of subepithelial collagen in asthma
and its sensitivity to drug therapy with combination of an inhaled glucocorticosteroid (GC) and
a long-acting b2-agonist (LABA), a cell model system involving bronchial fibroblasts derived from
biopsies from patients with stable mild-to-moderate asthma has been used. To mimic unstable
conditions and severeasthma,fibroblastswere stimulatedex vivowithTGFb1. Primaryfibroblasts
established fromcentral bronchial biopsies from8asthmaticpatientswere incubated for 24hwith
0.4% serum or TGFb1 (10 ng/ml) with/without the GC budesonide (BUD; 10 nM) and/or the LABA
formoterol (FORM; 0.1 nM). Procollagen peptide I (PICP), metalloproteinase (MMP)-1 and tissue
inhibitor of MMPs (TIMP-1) were determined in culture media using ELISA while the activity of
MMP-2, -3, -9 by zymography. Metabolically labeled proteoglycans, biglycan and decorin, associ-
ated with collagen fibrillation/deposition, were separated using chromatography and SDS-PAGE.
The levels of PICP and biglycan were increased 2-fold by TGFb1 (p < 0.05). The BUD and FORM
combination reduced the PICP increase by 58% (p< 0.01) and the biglycan by 36% (p< 0.05) while
each drug alone had no effect. Decorin levels were reduced by TGFb1 in fibroblasts of most
patients; BUD alone and BUD and FORM completely counteracted this decrease. MMPs and
TIMP-1were not affected by TGFb1 or the drugs. These results suggest that BUD and FORM combi-
nation therapy, without affecting metalloproteolytic balance, has a potential to counteract
enhanced collagen production by bronchial fibroblasts in asthma and to normalize the production
of small proteoglycans which may affect collagen fibrillation and deposition.
ª 2011 Published by Elsevier Ltd.6 222 33 14; fax: þ46 46 211 34 17.
n-Thorsson@med.lu.se (G. Westergren-Thorsson).
1 Published by Elsevier Ltd.
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Subepithelial fibrosis e thickened reticular basement
membrane as a result of enhanced deposition of various
extracellular matrix (ECM) molecules e is seen in airways of
patients with asthma of all severities.1e5 The extent of
subepithelial fibrosis is correlated with the clinical severity
of asthma and decrease in lung function.1e3,5,6 One of the
major constituents of the thickened reticular basement
membrane in asthma is collagen type I. In the process of
collagen type I formation, procollagen type I molecules are
released by fibroblasts, and as they are assembled into
insoluble collagen fibers, the soluble C-terminal peptide
procollagen type I (PICP) is removed into the extracellular
space. Hence, the PICP level in serum can be used as
a marker of ongoing collagen synthesis.7 In patients with
asthma, mean sputum PICP levels are several-fold higher
than those seen in healthy volunteers,8,9 are increased
during asthma exacerbations, and are negatively correlated
with patients’ forced expiratory volume in 1 s (FEV1)
expressed as a percentage of predicted normal value.8
Transforming growth factor b (TGFb) plays a prominent
role in formation of subepithelial fibrosis as it transforms
fibroblasts into more active myofibroblasts that are
responsible for enhanced production of various ECM
components, including collagens and proteoglycans.
Frequently, increased TGFb levels in the airways of asth-
matic patients correlate with the severity of asthma6 and
with the thickness of subepithelial basement membrane.10
According to a new paradigm for persistent asthma,
repeated exposures to allergens, respiratory viruses and
other environmental insults may lead to damaged epithe-
lium that does not heal completely or appropriately.11
Subepithelial collagen deposition in the airways of asth-
matic patients may be the result of an aberrant repair of
this “chronic wound”,12 and both enhanced collagen
production by submucosal fibroblasts and repressed
collagen turnover would increase collagen deposition. In
wound healing, as with organ morphogenesis, collagen
deposition and turnover are affected by collagen fibrillation
and organization of collagen fibers. Collagen deposition
requires formation of fibrillar collagen from soluble pro-
collagen molecules. The process of fiber assembly and
spatial organization depends in part on association with
small leucine-rich proteoglycans13 such as decorin14e16 and
biglycan.16e19 Decorin seems to be a key molecule in
regulation of collagen fibrillogenesis while biglycan can
fine-tune fibril assembly, especially early in the process,
and may provide partial functional compensation for
decorin deficiency.16,20,21 Deposition and turnover of
collagen are also affected by the balance between various
metalloproteinases (MMPs) and their main tissue inhibitor,
TIMP-1. The gelatinases MMP-9 and MMP-2 and collagenase
MMP-1 are main regulators of collagens while stromelysin
(MMP-3) affects turnover of proteoglycans22; all of these
MMPs have been detected in the airways of asthmatic
patients.23,24
Treatment of asthma with a combination therapy
comprising an inhaled glucocorticosteroid (GC) and a long-
acting b2-adrenergic agonist (LABA) has been shown to
result in improved asthma control.25e28 However, it remainsa matter of debate whether subepithelial fibrosis in asthma
may be counteracted by GC and LABA combination
therapy.29 Clinical studies addressing this issue are very few
in number30,31 and their results are fragmentary and
equivocal.
To further investigate the mechanisms of airway sub-
epithelial collagen deposition in asthma and its sensitivity
to drug therapy with a combination of inhaled GC and LABA,
we have used a cell model system involving bronchial
fibroblasts derived from biopsy samples taken from stable
mild-to-moderate patients with asthma. To mimic unstable
conditions, such as exacerbations and severe asthma,
bronchial fibroblasts were stimulated ex vivo with TGFb1.
We have investigated the TGFb1-induced synthesis of PICP,
biglycan and decorin. We have also analyzed the TGFb1-
induced production of TIMP-1 and MMP-1 as well as the
activity of MMP-9, MMP-2 and MMP-3. Concurrently with
TGFb1, patients’ bronchial fibroblasts were incubated ex
vivo with the GC budesonide (BUD) and the LABA formoterol
(FORM), either alone or in combination, to evaluate
whether combination therapy has the potential to coun-
teract subepithelial fibrosis and whether these drugs exert
their effects directly on the production of procollagen,
decorin and biglycan or act indirectly on ECM deposition
and degradation via effects on metalloproteolytic balance.Material and methodsPatients
Four female and four male patients, non-smokers, 25e55
years old, with stable mild-to-moderate asthma (according
to GINA guidelines: www.ginaasthma.org) and with
confirmed airway hyperresponsiveness to methacholine
were included in the study. A positive methacholine chal-
lenge test was defined as a fall in FEV1  20% (PD20) on
a cumulative dose of methacholine < 2000 mg, measured by
a tidal volume triggered technique (Automatic Provocation
System, Erich Ja¨ger GmbH, Ho¨chberg, Germany). Of the 8
patients, 5 had an FEV1% predicted normal of approxi-
mately 100% while 3 had values in the range of 62e67%;
these 3 patients had also the lowest PD20 values (<0.05 mg)
(Table 1). Only one of these 3 more severe patients showed
reversibility in FEV1 (defined as  12% improvement in FEV1
after inhalation of 400 mg salbutamol) and 2 of 5 patients
with mild disease (Table 1). All patients were atopic, with
skin prick tests confirming sensitization toward perennial
allergens, were free of infections during the six weeks
before bronchoscopy and used short-acting b2-adrenergic
agonists as needed. Patients were without inhaled corti-
costeroids during the last 6 months prior to the start of the
study because even in cases inhaled corticosteroids were
prescribed, the patients testified that they had not taken
any corticosteroid treatment. The study was reviewed and
approved by the Swedish Research Ethical Committee (No
LU339-00) and informed consent was obtained from all
patients. This study is linked to our previous study32 in
which the bronchial biopsy samples from the same patients
were used.
Table 1 Baseline characteristics of patients with asthma included in the study.
Sex Age (years) FEV1 (% predicted) PD20 (mg) FEV1 reversibility
Pt 1 F 28 101 60 N (4%)
Pt 2 F 31 104 15 Y (13%)
Pt 3 M 30 67 <0.05 N (5%)
Pt 4 F 25 95 20 Y (16%)
Pt 5 M 35 62 <0.05 Y (24%)
Pt 6 M 55 103 75 N (4%)
Pt 7 M 26 100 826 N (4%)
Pt 8 F 39 63 <0.05 N (5%)
Abbreviations: F Z female; M Z male; PD20 to methacholine stimulation; Y/N Z yes/no FEV1 reversibility was defined as  12%
improvement in FEV1 after 400 mg salbutamol.
1298 L. Todorova et al.Bronchoalveolar lavage and sampling of bronchial
tissue
Bronchoalveolar lavage (BAL) was performed in right middle
lobe with 150 ml buffered saline divided in three aliquots of
50 ml, and used for differential cell analysis. Bronchial
biopsy samples were collected from the second and third
bronchial generation from right lung as previously
described.33 Cells were collected from BAL fluid by cytospin
performed at1500 rpm for 5 min using a table cytocen-
trifuge (Shandon Southern Products Ltd., Runcorn, Chesh-
ire, UK). Cells were stained with May-Gru¨nwald and 6%
Giemsa solution in buffer (67 mM KH2PO4 and 67 mM
Na2HPO4) with separate rounds of buffer between staining.
Differential cell counts were performed on 100 cells using
light microscopy.Biopsy-derived bronchial primary fibroblasts
Primary fibroblast-like cells were established, as described
previously,32,33 from biopsy samples that were not different
in size, vascular or muscle content. Briefly, the biopsy
samples were cut into small pieces and were allowed to
adhere to cell culture plastic plates before the addition of
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented
with 10% fetal Clone III serum (Hyclone, Logan, UT, USA), 1%
L-glutamine, 0.5% gentamicin and 5 ug/ml amphotericin.
Biopsy samples were cultured until there were outgrowths
of cells with morphology typical for that of fibroblasts, i.e.
cells had a spindle-like shape and several protrusions.34,35
To ensure that true fibroblasts were cultured, markers for
fibroblasts and smooth muscle cells were used as previously
described.32 Isolated primary fibroblasts were split 1:2 at
expansions and were used in passages 4e6 for further
experiments.Study design
Biopsy-derived bronchial primary fibroblasts were cultured
in 6-well plates containing Earle’s minimal essential
medium (SigmaeAldrich, Irvine, UK) supplemented with
10% (v/v) Fetal Clone III serum (Hyclone, Logan, UT, USA),
1% L-glutamine, 0.5% gentamicin and 5 mg/ml amphotericin
at 37 C in a humidified 5% CO2 and 95% atmosphere.Prior to treatment with TGFb1 and drugs (or vehicle),
cells were starved for 2 h in DMEM supplemented with 1%
donor calf serum and 2 mM L-glutamine. Subsequently, cells
were incubated for 24 h with TGFb1 10 ng/ml (R&D
Systems, Minneapolis, MN, USA) in 0.4% serum and concur-
rently with BUD 108 M or FORM 1010 M or their combi-
nation (AstraZeneca, Lund, Sweden) in MgSO4-poor DMEM
(Gibco BRL, Paisley, UK). During the last 22 h of the incu-
bation, 50 mCi/ml [35S]-sulfate (PerkinElmer Life Science,
Boston, MA, USA) was also present. Fibroblasts incubated
with 0.4% serum and drug vehicle (0.1% ethanol) were used
as a baseline control. After incubation, the culture media
were collected and stored at 80 C with the exception of
the medium aliquots aimed for biglycan and decorin anal-
ysis; to these aliquots, 0.1% phenyl-methylsulphon-fluoride
(Sigma, St Louis, MO, USA) and 2 mM EDTA together with
0.1 mg/ml chondroitin sulfate-6 and 0.4 mg/ml dextran
were added and aliquots were stored at 20 C. Analyses of
PICP, biglycan, decorin, MMP-9, MMP-3, MMP-2, MMP-1 and
TIMP-1 were performed in culture media as described
below. All experiments with fibroblasts from each patient
were performed in homogenous, confluent cell cultures;
repeated two or three times, and mean value was calcu-
lated for each patient.
The concentration of BUD (108 M) and FORM (1010 M)
used in this study are regarded as clinical relevant; the BUD
concentration used reflects the concentration achieved in
the airway and lung tissue several hours after
inhalation36e38 while doses of FORM in asthma therapy are
typically two orders of magnitude lower than BUD doses.
Radiographic analysis of biglycan and decorin by
anion-exchange chromatography
Biglycan and decorin were obtained using radiographic
analysis by means of [35S]-sulfate incorporation into the
proteoglycan glycosaminoglycan chains and isolated using
anion-exchange chromatography as described previously.39
Briefly, unincorporated radioactive precursors from the
collected culture media applied to DEAE cellulose columns
were washed out whereon the proteoglycan fraction was
eluted and analyzed for [35S] sulfate activity. Eluted frac-
tions were then precipitated, separated, and identified on
gradient SDS-PAGE as described previously.39 The intensity
of the bands containing biglycan and decorin were further
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and related to the total protein content in the corre-
sponding cell layer using the BCA protein assay kit (Pierce
Chemical Co., Rockford, IL, USA).
Determination of PICP, MMP-1, and TIMP-1 by
immunoassay
The concentration of PICP released in the culture media
was measured by enzyme-linked immunosorbent assay
(ELISA) as recommended by the manufacturer (Takara
Biochemicals Co., Osaka, Japan). Concentrations of MMP-1
and TIMP-1 (TIMP-1 both as the free form as well as com-
plexed with MMPs) were analyzed by ELISA (Amersham, GE
Healthcare, Buckinghamshire, UK) according to the manu-
facturer’s instructions. The obtained concentrations were
related to the total protein content in the corresponding
cell layer using the BCA protein assay kit (Pierce Chemical
Co., Rockford, IL, USA).
Analysis of MMP-9, MMP-2 and MMP-3 by
zymography
The presence and activity of proteolytic enzymes were
analyzed using Novex polyacrylamide zymogram gels and
a prestained molecular-weight marker BluePlus2 Prestained
Standard (Invitrogen, Stockholm, Sweden) as described
previously.43 Briefly, the gelatinase activity of MMP-9 and
MMP-2 in the concentrated culture media was determined
by preactivating an equal volume of each sample with 1 mM
4-aminophenyl mercuric acetate (APMA) for 24e72 h and
then run on 10% zymogram under non-denaturing condi-
tions, all in accordance to the manufacturer’s instructions.
To determine the caseinolytic activity of MMP-3, samples
were preactivated with 5 mg/ml trypsin for 30 min at 37 C.
The activation was terminated by 2 mM phenyl-methyl-
sulphon-fluoride and samples were run on 4e16% zymogram
(prestained Blue Casein) at 125 V for 2 h at 4 C. The gels
were scanned and gelatinolytic and caseinolytic band areas
of activity were quantified by densitometric analysis of an
inverted display using a transformation tool program (BIO-
RAD’s software Quantity One) and expressed as optical
density related to the total protein content in the corre-
sponding cell layer using the BCA protein assay kit (Pierce
Chemical Co., Rockford, IL, USA).
Identification of MMP-9, MMP-2 and MMP-3 by
Western immunoblotting
The identification of the different MMPs was confirmed by
Western blot as described previously.43 In brief, equal
amounts of preactivated samples for MMP-9 and MMP-2
were subjected to 10% Tris-Glycine (Invitrogen, Stockholm,
Sweden), or 4e12% for MMP-3, and they were transferred
by electro-blotting to a PVDF-P Immobilon membrane
(Millipore, Bedford, MA, USA). The following primary anti-
bodies were applied for the various MMPs: MMP-2 mouse
anti-human monoclonal IgG/K, MMP-9 rabbit anti-mouse
(Gelatinase B) polyclonal full length, and rabbit anti-MMP-3
(Chemicon,Temecula, CA, USA); all were diluted 1:1000 in
TriseHCl, 150 mM NaCl, pH 7.5, 0.05% Tween with 1% BSA.As polyclonal secondary antibodies, rabbit anti-mouse-HRP
for MMP-2, swine anti-rabbit-HRP for MMP-9 and rabbit anti-
mouse-HRP for MMP-3 were used at a dilution of 1:1000
(DakoCytomation, Glostrup, Denmark). ECL Western Blot-
ting Detection Reagents (Amersham GE Healthcare) were
used for development and band visualization.
Statistical analysis
Data are shown for individual patients either in absolute
values or as a percentage of baseline control. For treat-
ment groups, data are presented as arithmetic
means  standard error of the mean (SEM). Data were
analyzed by 99% and 95% confidence interval analysis and
the results are reported as p < 0.01 and p < 0.05,
respectively. Differences were considered statistically
significant at p < 0.05. Analysis of each treatment group
(TGFb1 with vehicle or drugs) versus baseline control (0.4%
serum with drug vehicle) was performed on data expressed
as percentage of baseline control (where baseline
control Z 100) and checking whether the value of 100 is
included within the confidence intervals. The effects of the
drugs were analyzed as per cent inhibition of TGFb1
response and checking whether the zero value is included in
the confidence intervals; the per cent inhibition was
calculated as:
% inhibitionZ 100e100  (D e B)/(T e B), where D and
T are treatments with TGFb1 and drugs or TGFb1 and
vehicle, respectively, and B is a baseline control. The
correlation analysis was performed by testing the signifi-
cance of Pearson correlation coefficients (r) with t-test of
the regression. All analyses were performed using Astute
Software 1.5 (DDU Software, Leeds, UK).
Results
Cellular profile in BAL fluid
To assess the degree of inflammation in the airways of
asthmatic patients investigated in this study differential
analysis of cells in BAL fluid was performed, counting
monocytes/macrophages, lymphocytes, neutrophils eosin-
ophils, basophils and epithelial cells (Table 2). Heteroge-
neous results were obtained reflecting heterogeneity of the
patient population studied. Of the 8 patients investigated,
3 patients (Pt 3, Pt 5, Pt 8) had FEV1% predicted value below
70% and the lowest methacholine PD20 dose (<0.05 mg) and
5 patients had FEV1% predicted around 100% and meth-
acholine PD20 dose between 15 and 826 mg (Table 1). When
compared with the 5 patients with mild asthma, the 3
patients with moderate asthma had a somewhat higher
percentage of lymphocytes (12e24% vs.1.5e20%) and
a slightly lower percentage of monocytes/macrophages
(53e70% vs. 60e84%). The percentage of neutrophils and
eosinophils was very low in both groups (0e6%); however,
unexpectedly, it was higher in the mild asthma group.
Interestingly, the highest percentage of eosinophils
(2.5e6%) was seen in 3 patients with mild asthma of whom 2
patients (Pt 2 and Pt 4) were the only ones with reversible
FEV1 among the 5 patients with mild asthma, which might
suggest that these 2 patients were in a more active phase of
Table 2 Cellular profile in bronchoalveolar lavage fluid.
MO/MC (%) LYMPH (%) NEU (%) EOS (%) BASO (%) EPITH (%)
Pt 1 60.0 19.5 6.5 2.5 0.0 9.0
Pt 2 81.0 1.5 4.0 6.0 0.0 4.5
Pt 3 58.0 24.0 0.0 1.0 1.0 5.0
Pt 4 78.0 11.5 0.5 2.5 0.0 0.0
Pt 5 69.5 12.0 2.5 1.0 0.0 13.5
Pt 6 84.0 5.5 0.5 1.5 0.0 6.0
Pt 7 72.5 9.5 0.5 1.0 0.0 4.5
Pt 8 53.0 19.5 1.5 0.0 0.5 19.0
Abbreviations: MO/MCZ monocytes/macrophages; LYMPHZ lymphocytes; NEUZ neutrophils; EOSZ eosinophils; BASOZ basophils;
EPITH Z epithelial cells.
1300 L. Todorova et al.the disease. The percentage of epithelial cells in BAL fluid
was somewhat higher in the 3 patients with moderate
asthma (5e19%) than in those patients with mild asthma
(0e9%). An especially high percentage of epithelial cells
(13.5% and 19%) was seen in the two patients (Pt 5 and Pt 8,
respectively) with the lowest value of FEV1% predicted
(62e63%), which might suggest injured bronchial mucosa
with shedding epithelial cells.Extracellular matrix
Procollagen I
In bronchial fibroblasts from patients with asthma, 2 of the
3 patients with the lowest PD20 (<0.05 mg) and the lowest
(62e63%) FEV1% predicted (Pt 5 and Pt 8) showed from 2- to
11-fold higher baseline levels of PICP than the remaining
patients (Fig. 1A). TGFb1 increased PICP levels in 7 (of 8)
patients and decreased it in the remaining patient (Pt 8,
who in contrast to Pt 5 did not show FEV1 reversibility).
Interestingly, the greatest increase of PICP levels by TGFb1
(2.5e3.5-fold) was seen in the two patients (Pt 2 and Pt 4)
who were the only patients showing FEV1 reversibility
among the 5 patients with normal values of FEV1% pre-
dicted. These two patients had also the highest percentage
of eosinophils in BAL (Table 2). These results suggest that
PICP production may increase considerably in bronchial
fibroblasts from patients with mild asthma during less
stable periods of the disease. In contrast, in patients with
more severe asthma, PICP levels, although high, may be
more stable.
The average increase of PICP by TGFb1 in fibroblasts
from all 8 patients was 1.7-fold (p < 0.05) (Fig. 1A).
Concomitant incubation of fibroblasts with TGFb1 and BUD
or FORM had no significant effects whereas BUD and FORM
in combination decreased considerably variance between
PICP levels in fibroblasts from different patients and
significantly (p < 0.01) decreased PICP levels by an average
of 58% (Fig. 1B).
Biglycan
As with PICP levels, baseline levels of biglycan were the
highest in bronchial fibroblasts from the two patients with
the lowest lung function (Pt 5 and Pt 8) and this was
especially striking for Pt 8 with 50-fold higher levels than
those for other patients (Fig. 2A). Furthermore, exposure offibroblasts from these two patients to TGFb1 decreased the
production of biglycan while the production was increased
in fibroblasts from all the other patients. Overall, in fibro-
blasts from all 8 patients investigated, TGFb1 increased the
production of biglycan 2.2-fold (p < 0.05) (Fig. 2A).
Concurrent treatment with TGFb1 and the combination of
BUD and FORM decreased the production of biglycan by an
average of 36% (p < 0.05) whereas neither drug alone had
any significant effect (Fig. 2B). Again, the fibroblasts from
Pt 5 and Pt 8 deviated from this pattern; their production of
biglycan was increased or normalized to baseline levels by
all the drug treatments.
Decorin
As with PICP and biglycan, the highest baseline levels of
decorin were measured in bronchial fibroblasts from the two
patients with the lowest lung function (Pt 5 and Pt 8), dis-
playing from 1.5-fold up to 15-fold higher decorin levels than
those for fibroblasts from other patients investigated
(Fig. 3A). TGFb1 exposure decreased the production of
decorin by an average of 15% below baseline in bronchial
fibroblasts from all 8 patients investigated, however, this
decrease was not statistically significant. In fibroblasts from
the majority of patients, 5 of 8 (including the 3 patients with
more moderate asthma), the production of decorin was
decreased by TGFb1, while it was slightly increased in
fibroblasts from 2 patients (Pt 4 and Pt 7) and not affected in
one patient (Pt 6) (Fig. 3A). The greatest decrease of decorin
production by TGFb1 was seen in Pt 5 (who had the lowest
value of FEV1% predicted and the highest FEV1 reversibility
among the 8 patients investigated). The decrease of decorin
by TGFb1 in fibroblasts of 5 patients resulted in a level that
was on average 40% below baseline (p < 0.01). Concurrent
treatment with TGFb1 and BUD alone or in combination with
FORM completely counteracted this decrease whereas FORM
alone significantly (p < 0.01) attenuated it to the levels 15%
below baseline (Fig. 3B).Metalloproteolytic balance
MMP-9 and MMP-2
Gelatin zymography followed by Western blot showed
enzymatic activity of MMP-9 in fibroblast medium as an 82-
kDa band (Fig. 4A), while the 92-kDa band of the pro-form
was often not visible. Activity of MMP-2 was seen as a 62-
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Figure 1 Concentration of procollagen I carboxyterminal
propeptide (PICP) in culture media of bronchial fibroblasts
from asthmatic patients, and the effects of budesonide and
formoterol in fibroblasts stimulated with transforming growth
factor b1 (TGFb1; 10 ng/ml) for 24 h. PICP was measured by
ELISA and normalized to the total protein content in the cor-
responding cell layer. A: PICP concentration (ng/mg protein) at
baseline conditions (incubation of fibroblasts with 0.4% serum)
and after stimulation of fibroblasts with TGFb1. B: The effects
of treatment with TGFb1 alone or with concurrent budesonide
108 M (B8) and/or formoterol 1010 M (F10) expressed as
a percentage of PICP concentration at baseline (where base-
line Z 100%). Symbols represent individual patients (Pt): Pt
1 Z open triangle, Pt 2 Z star, Pt 3 Z closed diamond, Pt
4 Z open diamond, Pt 5 Z closed square, Pt 6 Z open circle,
Pt 7Z open square, Pt 8Z closed triangle. Means are shown as
horizontal bars. )p < 0.05, ))p < 0.01 versus baseline;
##p < 0.01 versus TGFb1.
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Figure 2 Concentration of the small leucine-rich proteo-
glycan, biglycan, in culture media of bronchial fibroblasts from
asthmatic patients, and the effects of budesonide and for-
moterol in fibroblasts stimulated with transforming growth
factor b1 (TGFb1; 10 ng/ml) for 24 h. Biglycan was measured by
means of [35S]-sulfate incorporation into the proteoglycan
glycosaminoglycan chains and using anion-exchange chroma-
tography. Biglycan was identified on gradient SDS-PAGE and the
radioactive intensity (expressed as disintegration per minute;
dpm) was normalized to the total protein content in the cor-
responding cell layer. A: Biglycan concentration (dpm/mg
protein) at baseline conditions (incubation of fibroblasts with
0.4% serum) and after stimulation of fibroblasts with TGFb1. B:
The effects of treatment with TGFb1 alone or with concurrent
budesonide 108 M (B8) and/or formoterol 1010 M (F10)
expressed as a percentage of biglycan concentration at base-
line (where baseline Z 100%). Symbols represent individual
patients and are shown as in Fig. 1. Means are shown as hori-
zontal bars. )p < 0.05, ))p < 0.01 versus baseline; #p < 0.05
versus TGFb1.
Budesonide/formoterol effects on matrix production 1301kDa band and a pro-form 72-kDa band (Fig. 4A). A slight
increase of MMP-9 activity (18%) and MMP-2 activity (14%)
by TGFb1 was not statistically significant and the concur-
rent treatment with BUD and/or FORM had no significant
effects on MMP-9 and MMP-2 activity (Fig. 4B and C). The
results on both MMP-9 and MMP-2 showed very high
heterogeneity. Interestingly, for MMP-9 this was mainly
because of the high levels in fibroblasts from the patient
with the lowest FEV1% predicted value and the lowest PD20
dose measured (Pt 5), while for MMP-2 this was to the result
of the high levels from the patient (Pt 7) who had normalFEV1% predicted value and the highest PD20 dose among all
the patients investigated.
MMP-3
Casein zymography followed by Western blot showed
enzymatic activity of MMP-3 in fibroblast medium as an
active band at 45 kDa, a pro-form double band at 57/59 kDa
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Figure 3 Concentration of the small leucine-rich proteo-
glycan, decorin, in culture media of bronchial fibroblasts from
asthmatic patients, and the effects of budesonide and for-
moterol in fibroblasts stimulated with transforming growth
factor b1 (TGFb1; 10 ng/ml) for 24 h. Decorin was measured by
means of [35S]-sulfate incorporation into the proteoglycan
glycosaminoglycan chains and using anion-exchange chroma-
tography. Decorin was identified on gradient SDS-PAGE and the
radioactive intensity (expressed as disintegration per minute;
dpm) was normalized to the total protein content in the corre-
sponding cell layer. A: Decorin concentration (dpm/mg protein)
at baseline conditions (incubation of fibroblasts with 0.4%
serum) and after stimulation of fibroblasts with TGFb1. B: The
effects of treatment with TGFb1 alone or with concurrent
budesonide 108 M (B8) and/or formoterol 1010 M (F10)
expressed as a percentage of decorin concentration at baseline
(where baseline Z 100%) in fibroblasts from 5 (of 8) patients
showing decreased decorin production after stimulation with
TGFb1. Symbols represent individual patients and are shown
as in Fig. 1. Means are shown as horizontal bars. )p < 0.05,
))p< 0.01 versus baseline; #p< 0.05, ##p< 0.01 versus TGFb1.
1302 L. Todorova et al.and a complexed form around 100 kDa (Fig. 5A). After
stimulation with TGFb1, MMP-3 activity slightly decreased
(14% below baseline) but this decrease was not statistically
significant and concurrent treatment with BUD and/or
FORM had no significant effects on MMP-3 activity (Fig. 5B).
The high heterogeneity of MMP-3 activity seen afterexposure to TGFb1 increased further after concurrent drug
treatments.
MMP-1
Collagen zymography for analysis of MMP-1 activity was not
commercially available and therefore we have measured
MMP-1 protein by ELISA. TGFb1 had no significant effect (an
increase of 2.5%) on MMP-1 protein and the concurrent
treatment with BUD and/or FORM had no significant effects
on MMP-1 levels (Fig. 6). A high heterogeneity in these data
was largely to the result of the heterogeneous contribution
of fibroblasts from the patients with the lowest FEV1%
predicted value; the high levels from Pt 8 and low levels
from Pt 5. However, the greatest increase of TIMP-1 protein
(2-fold) induced by TGFb1 was seen in fibroblasts from the
patient (Pt 4) who had the greatest FEV1 reversibility (16%)
among the 5 patients with normal FEV1% predicted values.
In this patient, all the drug treatments concurrent with
TGFb1 lowered MMP-1 protein levels.
TIMP-1
TIMP-1 levels were measured by ELISA. TGFb1 had no
significant effect (an increase of 6.8%) on TIMP-1 protein
and there were no significant effects of concurrent treat-
ment with BUD and/or FORM on TIMP-1 levels (Fig. 7). As for
MMP-1, the greatest increase of TIMP-1 protein (1.6-fold)
induced by TGFb1 was seen in fibroblasts from the patient
(Pt 4) who had the greatest FEV1 reversibility (16%) among
the 5 patients with normal FEV1% predicted values.
However, in contrast to MMP-1, the drug treatments
concurrent with TGFb1 did not decrease TIMP-1 protein
level in this patient. Interestingly, in the fibroblasts from
the second patient (Pt 2) with FEV1% reversibility (13%)
among the 5 patients with normal FEV1% predicted values,
TGFb1 exposure resulted in a decrease of TIMP-1 levels
below baseline but this was counteracted by both FORM
alone and the combination of FORM and BUD.Discussion
We have shown in the present study that following ex vivo
exposure to TGFb1, bronchial fibroblasts derived from
biopsy samples from patients with asthma increased their
production of PICP, a marker of ongoing collagen I
synthesis, and that the combination treatment of BUD and
FORM counteracted this increase while neither drug alone
had any significant effect. Similarly, the TGFb1-induced
increase of a small proteoglycan, biglycan, was reduced by
the BUD and FORM combination but not by either drug
alone. Additionally, in fibroblasts from 5 of 8 patients, TGF
b1 decreased production of another small proteoglycan,
decorin, and this decrease was completely counteracted by
BUD alone and the BUD and FORM combination. Both
decorin and biglycan may affect collagen deposition in the
ECM since they are involved in fibrillation of collagen fibers
and organization of collagen network. In contrast to pro-
collagen and small proteglycans, TGFb1, BUD and FORM did
not affect the production or activity of the various MMPs
investigated and their main tissue inhibitor TIMP-1. These
results suggest that BUD and FORM combination therapy has
a potential to counteract enhanced collagen production
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Figure 4 Activity of MMP-9 and MMP-2 in culture media of
bronchial fibroblasts from asthmatic patients, and the effects
of budesonide and formoterol in fibroblasts stimulated with
transforming growth factor b1 (TGFb1; 10 ng/ml) for 24 h. A:
Representative gelatin zymogram and Western blot (WB)
revealing both the presence and enzymatic activity of MMP-9
and MMP-2 in culture media at baseline conditions (incubation
of fibroblast with 0.4% serum) and after stimulation of fibro-
blasts with TGFb1 alone or with budesonide 108 M (B8) and/or
formoterol 1010 M (F10). Enzymatic activity for MMP-9 was
seen at 82 kDa, slightly visible pro-form enzyme at 92 kDa and
high molecular-weight complexes above 100 kDa. For MMP-2,
the active enzyme was seen at 62 kDa and the pro-form
enzyme at 72 kDa. The activity of the MMP-9 and MMP-2 at
82 kDa and 62 kDa, respectively, was quantified by densito-
metric analysis of inverted displays and normalized to the total
protein content in the corresponding cell layer. B and C: The
Budesonide/formoterol effects on matrix production 1303and deposition in ECM by bronchial fibroblasts in asthma
without affecting metalloproteolytic balance.
The group of 8 patients with mild-to-moderate asthma
investigated in the present study was very heterogeneous.
They were between 25 and 55 years old, 5 patients had
FEV1% predicted value around 100% while this was below
70% for the remaining 3 patients who also had the lowest
value of methacholine PD20 dose, indicating that these
patients had more severe asthma. Two of the 5 patients
with normal lung function, and only one patient of the 3
patients with low FEV1% predicted, showed FEV1 revers-
ibility. This clinical heterogeneity was reflected by the
cellular profile of BAL fluid. The highest percentage of
eosinophils in BAL fluid was seen in 2 patients with normal
lung function but who showed FEV1 reversibility, which may
suggest that these patients were in a more active phase of
the disease. The highest percentage of epithelial cells was
seen in the 2 patients with the lowest value of FEV1% pre-
dicted, which may suggest ongoing remodeling of injured
bronchial epithelium. Interestingly, the same 4 patients
with the highest percentage of eosinophils, or epithelial
cells in BAL fluid, had the greatest impact on the hetero-
geneity of the production of PICP, biglycan and decorin and
on activities or levels of MMPs and TIMP-1 in their bronchial
fibroblasts after stimulation ex vivo with TGFb1.
In the same 8 patients as investigated in this study, we
have recently reported that patients’ FEV1% predicted and
methacholine log PD20 values were negatively correlated
with PICP synthesized by patients’ bronchial fibroblasts ex
vivo at baseline conditions while the respective negative
associations for proteoglycan production were not statisti-
cally significant.32 In the present study we have investi-
gated these relationships for PICP, biglycan and decorin
after stimulation of fibroblasts with TGFb1; however, no
significant correlations were found (data not shown).
TGFb1 stimulation was used to mimic unstable conditions
and more severe asthma since the collection of biopsies
during exacerbations or in severe disease is not feasible.
Indeed, in asthma of all severities (mild and moderate-to-
severe), TGFb protein expression in bronchial biopsy tissue
is increased and positively correlates with disease
severity.41 The significance of TGFb in airway remodeling is,
in a large part, to the result of its ability to induce
a differentiation of fibroblasts into myofibroblasts, which
produce a variety of ECM components, including collagen
and proteoglycans. Recently, it was shown that an increase
of the numbers of submucosal tissue myofibroblasts after
allergen inhalation by asthmatic patients was counteracted
by inhaled BUD and FORM combination therapy, but not by
inhaled BUD alone.31
TGFb is associated with increased expression of collagen
type I and III in bronchial tissue.41 Increased ongoing
collagen type I production is reflected by increased PICPeffects of treatment with TGFb1 alone or with concurrent
budesonide 108 M (B8) and/or formoterol 1010 M (F10) on
MMP-9 (B) and MMP-2 activity (C); the effects are expressed as
a percentage of the activity at baseline (where base-
line Z 100%). Symbols represent individual patients and are
shown as in Fig. 1. Means are shown as horizontal bars. There
were no statistical significant differences between treatment
groups.
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Figure 5 Activity of MMP-3 in culture media of bronchial
fibroblasts from asthmatic patients and the effects of bude-
sonide and formoterol in fibroblasts stimulated with trans-
forming growth factor b1 (TGFb1; 10 ng/ml) for 24 h. A:
Representative casein zymogram and Western blot (WB)
revealing both the presence and enzymatic activity of MMP-3 at
baseline conditions (incubation of fibroblast with 0.4% serum)
and after stimulation of fibroblasts with TGFb1. The active
enzyme was seen at 45 kDa, slightly visible pro-form enzyme
appeared as a double band at 57/59 kDa, and a complex form
around 100 kDa. MMP-3 activity at 45 kDa was quantified by
densitometric analysis of the active band inverted display and
normalized to the total protein content in the corresponding
cell layer. B: The effects of treatment with TGFb1 alone or
with concurrent budesonide 108 M (B8) and/or formoterol
1010 M (F10) expressed as a percentage of the activity at
baseline (where baseline Z 100%). Symbols represent indi-
vidual patients and are shown as in Fig. 1. Means are shown as
horizontal bars. There were no statistical significant differ-
ences between treatment groups.
0
50
100
150
200
250
T
G
F
ß
1
-
in
d
u
c
e
d
 M
M
P
-
1
 
(
b
a
s
e
li
n
e
=
1
0
0
)
TGFß1 TGFß1+B8 TGFß1+F10 TGFß1+B8+F10
Figure 6 Concentration of MMP-1 in culture media of bron-
chial fibroblasts from asthmatic patients, and the effects of
budesonide and formoterol in fibroblasts stimulated with
transforming growth factor b1 (TGFb1; 10 ng/ml) for 24 h.
MMP-1 was measured by ELISA and normalized to the total
protein content in the corresponding cell layer. The effects of
treatment with TGFb1 alone or with concurrent budesonide
108 M (B8) and/or formoterol 1010 M (F10) expressed as
a percentage of MMP-1 concentration at baseline (where
baseline Z 100%). Symbols represent individual patients and
are shown as in Fig. 1. Means are shown as horizontal bars.
There were no statistical significant differences between
treatment groups.
1304 L. Todorova et al.release, and indeed, PICP sputum levels are enhanced in
patients with asthma,8,9 are further increased during
exacerbations8 and inversely correlate with FEV1% pre-
dicted normal.8 In the study by Kai et al.,9 PICP levels in
sputum from patients with asthma were decreased
approximately 30% by inhaled GC, fluticasone propionate
(800 mg for 1 month). In the current study, TGFb1 increased
PICP production by bronchial fibroblasts approximately
2-fold and this increase was reduced by almost 60% by BUD
and FORM combination treatment while the decrease byBUD alone was not statistically significant. This suggests
that inhaled GC and LABA combination therapy may be
more efficient than inhaled GC alone in counteracting
increased procollagen production and perhaps also collagen
deposition in the airways of asthmatic patients.
Collagen deposition requires formation of fibrillar
collagen from soluble procollagen molecules and this
process depends, in part, on association with small leucine-
rich proteoglycans e mainly decorin14e16 but also the
structurally related biglycan.17e19 Both decorin and bigly-
can are associated with the deposition of collagen type
I17,42,43 and this may suggest they have a pro-fibrotic
function. On the other hand, decorin has been shown to
neutralize the biological activity of TGFb44,45 and thus act
against the development of fibrosis. Indeed, decorin has
been shown to prevent scar formation in vivo46 and to
reduce the development of lung fibrosis in a murine
model.45 In the present study, exposure of bronchial fibro-
blasts to TGFb1 doubled their production of biglycan while
decorin production was not significantly affected when all
patients investigated were taken into account. However, in
fibroblasts from 5 of 8 patients, decorin production was
significantly decreased by 40% below baseline level. The
differential regulation of biglycan versus decorin by TGFb1
was previously shown in human skin fibroblasts,47 a human
lung fibroblast cell line (HFL-1)49 and in a pulmonary fibrosis
model in rats,49 where TGFb1 increased biglycan produc-
tion but either had no effect on decorin production48 or
decreased it.47,49 This suggests that these small proteo-
glycans can be independently regulated by TGFb1. Impor-
tantly, increased density of biglycan but decreased density
of decorin were also found in the bronchial subepithelial
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Figure 7 Concentration of TIMP-1 in culture media of bron-
chial fibroblasts from asthmatic patients, and the effects of
budesonide and formoterol in fibroblasts stimulated with
transforming growth factor b1 (TGFb1; 10 ng/ml) for 24 h.
TIMP-1 was measured by ELISA and normalized to the total
protein content in the corresponding cell layer. The effects of
treatment with TGFb1 alone or with concurrent budesonide
108 M (B8) and/or formoterol 1010 M (F10) expressed as
a percentage of TIMP-1 concentration at baseline (where
baseline Z 100%). Symbols represent individual patients and
are shown as in Fig. 1. Means are shown as horizontal bars.
There were no statistical significant differences between
treatment groups.
Budesonide/formoterol effects on matrix production 1305layer of patients with mild asthma compared with the
normal control group.50
In the current study, TGFb1-induced decrease of decorin
production by bronchial fibroblasts from asthmatic patients
was completely reversed by BUD alone and also the
combination of BUD and FORM. In contrast, the increased
production of PICP and biglycan by TGFb1 was significantly
inhibited only by the combination of BUD and FORM but not
by BUD alone. These results suggest that the combination
therapy of BUD and FORM may be more effective at coun-
teracting subepithelial fibrosis in the airways of asthma
patients than BUD alone. Indeed, in mild asthma, 4-week
treatment with inhaled budesonide did not reduce basal
membrane thickening51 and high doses of inhaled flutica-
sone propionate for 8 weeks did not affect collagen dep-
osition under the basement membrane.52 Moreover,
a 2-week course of oral prednisolone did not decrease
collagen type I in the submucosa of patients with moderate-
to-severe asthma.41 In contrast, therapy with moderate
doses of inhaled BUD and FORM for 3 months in patients
with mild-to-moderate asthma significantly diminished the
thickness of the bronchial reticular basement membrane
and normalized the bronchial wall thickness and
diameter.30
We have previously shown in the human lung fibroblast
cell line (HFL-1) that TGFb1 increased activity of MMP-2, -3
-9 and TIMP-1 and that BUD and FORM in combination
increased the MMP-2/TIMP-1 and MMP-3/TIMP-1 ratios via
a decrease of TIMP-1.40 These results suggest that the
combination of BUD and FORM treatment may counteract
excessive ECM deposition by increasing fibroblast metal-
loproteolytic activity. However, in the present studyperformed in biopsy-derived bronchial fibroblasts from
asthmatic patients, ex vivo exposure to TGFb1 in the
absence or presence of BUD and/or FORM had no effects on
MMPs or TIMP-1. Thus, these results suggest direct inhibi-
tory effects of BUD and FORM combination therapy on the
TGFb1-modified production of procollagen type I, biglycan
and decorin.
It was recently shown that a GC, dexamethasone,
decreased production of procollagen type I in bronchial
fibroblasts isolated from normal donors but not from asth-
matic patients and this appeared to be related to increased
expression of activator protein-1 (AP-1) transcription factor
in bronchial fibroblasts from asthmatic patients.53 Thus,
excessive amounts of AP-1 may reduce the number of
activated GR in nuclei and by this mechanism impair GC
effects on gene transcription. b2-Adrenergic agonists are
known to increase translocation of GRs from the cytoplasm
into the nucleus in various cells including primary human
lung fibroblasts.54 This phenomenon may explain the
suppressive effects of BUD and FORM combination treat-
ment on TGFb1-induced PICP production in the present
study but lack of the effect of BUD alone. We have also
previously shown that the inhibitory effects of BUD and
FORM combination treatment on the total proteglycan
production (induced by serum in HFL-1 cells) were depen-
dent on the presence of functional GRs as well as
b-adrenoceptors.39
In conclusion, we have shown here that in biopsy-derived
bronchial fibroblasts from stable, mild-to-moderate patients
with asthma, TGFb1-increased synthesis of procollagen type
I was directly counteracted by the combination of BUD and
FORM but not by either drug alone. The combination of BUD
and FORM also normalized production of small proteoglycans
which may affect collagen fibrillization, organization and
deposition. Importantly, these effects were achieved
without affecting metalloproteolytic balance. These results
suggest that BUD and FORM combination therapy has
a potential to counteract enhanced collagen production and
deposition by bronchial fibroblasts in asthma.
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